Kymera Therapeutics, Inc. $KYMR is Siren L.L.C.’s 2nd Largest Position

Siren L.L.C. decreased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 3.0% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 3,186,830 shares of the company’s stock after selling 100,000 shares during the period. Kymera Therapeutics accounts for 7.4% of Siren L.L.C.’s portfolio, making the stock its 2nd biggest position. Siren L.L.C.’s holdings in Kymera Therapeutics were worth $265,431,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. US Bancorp DE lifted its position in Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after acquiring an additional 166 shares during the last quarter. Cetera Investment Advisers boosted its stake in Kymera Therapeutics by 7.5% in the first quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock valued at $300,000 after acquiring an additional 252 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Kymera Therapeutics by 36.9% during the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after purchasing an additional 287 shares during the last quarter. Swiss National Bank increased its position in shares of Kymera Therapeutics by 0.3% during the first quarter. Swiss National Bank now owns 94,500 shares of the company’s stock worth $7,871,000 after purchasing an additional 300 shares in the last quarter. Finally, AlphaCentric Advisors LLC increased its position in shares of Kymera Therapeutics by 6.1% during the first quarter. AlphaCentric Advisors LLC now owns 5,342 shares of the company’s stock worth $445,000 after purchasing an additional 307 shares in the last quarter.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR opened at $110.38 on Friday. Kymera Therapeutics, Inc. has a one year low of $36.65 and a one year high of $130.05. The stock has a market capitalization of $9.08 billion, a price-to-earnings ratio of -30.92 and a beta of 1.95. The company has a 50-day simple moving average of $95.67 and a 200-day simple moving average of $86.38.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The firm had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business’s revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.82) earnings per share. As a group, research analysts forecast that Kymera Therapeutics, Inc. will post -3.28 EPS for the current fiscal year.

Analyst Ratings Changes

KYMR has been the subject of a number of research analyst reports. Truist Financial upped their target price on Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Bank of America lifted their price target on Kymera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Loop Capital set a $97.00 price objective on Kymera Therapeutics in a report on Monday, June 8th. Finally, BTIG Research restated a “buy” rating and set a $134.00 target price on shares of Kymera Therapeutics in a research report on Thursday, June 25th. Twenty research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $122.64.

Insider Activity at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 77,109 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the completion of the sale, the chief financial officer owned 244,883 shares in the company, valued at $28,151,749.68. This represents a 23.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Nello Mainolfi sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $119.00, for a total value of $5,950,000.00. Following the sale, the chief executive officer owned 666,568 shares of the company’s stock, valued at $79,321,592. This trade represents a 6.98% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 3,637,813 shares of company stock worth $390,253,404 in the last ninety days. Company insiders own 15.98% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.